IN2013MU01431A - - Google Patents
Download PDFInfo
- Publication number
- IN2013MU01431A IN2013MU01431A IN1431MU2013A IN2013MU01431A IN 2013MU01431 A IN2013MU01431 A IN 2013MU01431A IN 1431MU2013 A IN1431MU2013 A IN 1431MU2013A IN 2013MU01431 A IN2013MU01431 A IN 2013MU01431A
- Authority
- IN
- India
- Prior art keywords
- abstract
- solvents
- derived
- novel
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 4
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229960001467 bortezomib Drugs 0.000 abstract 1
- -1 bortezomib mannitol ester Chemical class 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2909519A CA2909519A1 (en) | 2013-04-16 | 2014-04-16 | Process for the preparation of bortezomib mannitol ester |
ZA2014/02789A ZA201402789B (en) | 2013-04-16 | 2014-04-16 | Process for the preparation of bortezomib mannitol ester |
US14/784,866 US10023611B2 (en) | 2013-04-16 | 2014-04-16 | Process for the preparation of bortezomib mannitol ester |
IN1431MU2013 IN2013MU01431A (enrdf_load_stackoverflow) | 2013-04-16 | 2014-04-16 | |
PCT/GB2014/000150 WO2014170628A1 (en) | 2013-04-16 | 2014-04-16 | Process for the preparation of bortezomib mannitol ester |
EP14719344.5A EP2986619A1 (en) | 2013-04-16 | 2014-04-16 | Process for the preparation of bortezomib mannitol ester |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1431MU2013 IN2013MU01431A (enrdf_load_stackoverflow) | 2013-04-16 | 2014-04-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2013MU01431A true IN2013MU01431A (enrdf_load_stackoverflow) | 2015-06-26 |
Family
ID=50549349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1431MU2013 IN2013MU01431A (enrdf_load_stackoverflow) | 2013-04-16 | 2014-04-16 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10023611B2 (enrdf_load_stackoverflow) |
EP (1) | EP2986619A1 (enrdf_load_stackoverflow) |
CA (1) | CA2909519A1 (enrdf_load_stackoverflow) |
IN (1) | IN2013MU01431A (enrdf_load_stackoverflow) |
WO (1) | WO2014170628A1 (enrdf_load_stackoverflow) |
ZA (1) | ZA201402789B (enrdf_load_stackoverflow) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10023611B2 (en) | 2013-04-16 | 2018-07-17 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3288955T (pt) * | 2015-04-29 | 2020-01-06 | Nanosilical Devices Srl | Sistema de entrega à base de bortezomib |
US10144761B2 (en) | 2015-06-19 | 2018-12-04 | Hanlin Scientific Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
PT109941B (pt) * | 2017-03-02 | 2021-02-09 | Hovione Farmaciência, S.A. | Conjugados de boro multifuncionais com uma estrutura tripodal, composições farmacêuticas e processos de preparação dos mesmos |
EP3908258A4 (en) * | 2019-01-11 | 2022-09-28 | Intas Pharmaceuticals Ltd. | METHOD FOR PREPARING A STABLE PHARMACEUTICAL COMPOSITION OF BORTEZOMIB |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
EP0979096B1 (en) | 1997-02-15 | 2003-05-14 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts through inhibition of nf-kappab |
AU9580098A (en) | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
US6699835B2 (en) * | 2001-01-25 | 2004-03-02 | The United States Of America As Represented By The Department Of Health And Human Services | Formulation of boronic acid compounds |
AU2005230930B2 (en) | 2004-03-30 | 2011-09-29 | Millennium Pharmaceuticals, Inc. | Synthesis of boronic ester and acid compounds |
WO2008075376A1 (en) * | 2006-12-18 | 2008-06-26 | Natco Pharma Limited | Polymorphic forms of bortezomib and process for their preparation |
WO2009004350A1 (en) | 2007-07-03 | 2009-01-08 | Pliva Hrvatska D.O.O. | Methods for preparing bortezomib and intermediates used in its manufacture |
JP2010539183A (ja) | 2007-09-12 | 2010-12-16 | ドクター・レディーズ・ラボラトリーズ・リミテッド | ボルテゾミブおよびその生成のためのプロセス |
WO2010039762A2 (en) * | 2008-10-01 | 2010-04-08 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising boronic acid compounds |
WO2010146176A2 (en) | 2009-06-19 | 2010-12-23 | Lek Pharmaceuticals D.D. | Process for hydrogenation of halogenoalkenes without dehalogenation |
AU2010341530B2 (en) | 2009-12-22 | 2016-03-10 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
AU2011214024A1 (en) | 2010-02-09 | 2012-08-30 | Ranbaxy Laboratories Limited | Process for the preparation of bortezomib |
WO2012048745A1 (en) | 2010-10-14 | 2012-04-19 | Synthon Bv | Process for making bortezomib and intermediates for the process |
US9505787B2 (en) | 2012-09-11 | 2016-11-29 | Cipla Limited | Process for preparing of bortezomib |
US10023611B2 (en) | 2013-04-16 | 2018-07-17 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
-
2014
- 2014-04-16 US US14/784,866 patent/US10023611B2/en not_active Expired - Fee Related
- 2014-04-16 CA CA2909519A patent/CA2909519A1/en not_active Abandoned
- 2014-04-16 IN IN1431MU2013 patent/IN2013MU01431A/en unknown
- 2014-04-16 WO PCT/GB2014/000150 patent/WO2014170628A1/en active Application Filing
- 2014-04-16 ZA ZA2014/02789A patent/ZA201402789B/en unknown
- 2014-04-16 EP EP14719344.5A patent/EP2986619A1/en not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10023611B2 (en) | 2013-04-16 | 2018-07-17 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
Also Published As
Publication number | Publication date |
---|---|
US10023611B2 (en) | 2018-07-17 |
EP2986619A1 (en) | 2016-02-24 |
ZA201402789B (en) | 2015-11-25 |
WO2014170628A8 (en) | 2014-12-18 |
CA2909519A1 (en) | 2014-10-23 |
US20160075736A1 (en) | 2016-03-17 |
WO2014170628A1 (en) | 2014-10-23 |